Tagged with A

FPS - Facophar Santé FPS is a hundred year old organization with roots in the beginning of the last century representing today SME suppliers to the health industries. Given the variety of its membership what are the current priorities of FPS and how does the organization stay relevant to its multiple industries? Firstly I…

LEEM - Les Enterprises du Medicament Throughout your prolific career in the pharmaceutical industry, what would you describe have been the major changes in the French pharmaceutical market and to what extent has France kept up? I think France has kept up with the world market albeit with some notable differences, namely in terms of our…

France Biotech France is a major pharmaceutical market, leader in Europe and number three in the world but it seems in biotechnologies, France lags behind. In your opinion, what has caused this? In fact, there were some delays in consciousness of the biotech trend. Compared to other countries, it took more time…

France What was the idea behind the creation of the « Etats Generaux de l’industrie » (General States of Industries)? What can we expect from them? The main idea is that we can no longer live during this crisis without letting people express themselves genuinely. And I don’t mean expression of…

Paion Why was the time right in 2000 to start Paion, and how did your background and experiences in the pharma industry, academia and consulting help you create the successful company we see today? The reason for founding Paion in 2000 was more a question of timing of our own development.…

Hikma Pharma One of the biggest recent milestones for Hikma’s global operations must have been the acquisition of Ribosepharm and Thymoorgan in 2007. How successfully have the two companies integrated into the Hikma organisation, and how important are Hikma’s German operations for the company today? Hikma first established operations in Germany in…

Biomax Informatics Your interest in bioinformatics has run though your academic career and now into your business career as CEO and founder of Biomax Informatics; what was your vision for the company and how successful have you been so far in achieving your aims? When I founded the company 10 years ago,…

GlaxoSmithKline Given the heated debate over NHS reform and the new revised bill proposed by the government, what are you current priorities as President of the ABPI and how have these evolved since you stepped into that role in April 2010? The ABPI represents the R&D and innovation-based pharmaceutical companies in…

IMS Health Germany Could you give us a brief introduction to IMS’ business model? What would you say are the main challenges encountered today in the German market for IMS? IMS has been the partner of the pharmaceutical industry for over fifty years and has evolved alongside it. IMS today is the partner…

DKFZ - German Cancer Research Center The DKFZ – German Cancer Research Center – is Germany’s largest cancer research institute with an international recognition recently coroneted with the Nobel Prize to Mr Harald zur Hausen for the HPV vaccine. What were the set of values and visions that allowed the DKEZ to have such a prominent…

VFA 2007 was a turning point for the German Pharmaceutical Industry as the Healthcare Reform from 2007 took place and the Special SHI enhancement Act entered into force. Two years down the line, how have these two events affected the industry, especially the members of the VFA, the German Association of…

Pfizer Argentina You were General Manager of Pfizer Peru and Pfizer Venezuela before taking on the challenge of the Argentinean market. How difficult was the experience of adjusting to this unique environment? One of the things that a manager learns quickly in Latin America is how to deal with the volatility and…